clones

By mapping the evolution of cancer cells in patients with myelodysplastic syndromes who later died of leukemia, Timothy Graubert, Matthew Walter and their Washington University colleagues have found clues to suggest that targeted cancer drugs should be aimed at mutations that develop early in the disease.